Why Are Medifil II Collagen Particles Different?
Although collagen particles are not new to the market, they have recently become one of the most popular advanced wound care products, particularly among surgeons and podiatric physicians. Collagen particles can be incredibly useful as more physicians and wound care professionals explore more rapid and cost-efficient ways to improve wound healing.
What you remove from a wound (devitalized tissue) is still more significant than what you put on it. However, no matter what you put on a wound, proper wound debridement, offloading, and moisture balance are essential. Keeping a wound free of debris is still significant for wound healing. While the ease of use and low cost are the most evident advantages of collagen particles, the particle form of a collagen protein provides direct bioavailability for the wound bed, promoting wound healing.
Medifil® II Collagen Particles enable increased diffusion across the wound bed’s surface, in addition to quick absorption. The body’s natural tissue repair is stimulated by increased wound contact and bioavailability. A better understanding of collagen’s natural form and function in wound healing has aided practitioners in better understanding their wound healing options.
Medifil® II Collagen Particles are collagen in their “purest form”. Non-hydrolyzed collagen retains a higher percentage of its native triple helix protein structure, providing for greater molecular and scaffold stability during wound healing. To improve thermal endurance, mechanical strength, and the ability to engage in precise interactions with other biomolecules, collagen must maintain its triple helix form.
Type 1 collagen is required for the extracellular matrix to produce growth factors, as well as to store and retain growth factors. When the extracellular matrix is disrupted during hydrolysis, tissue loss and bacterial proliferation are possible. Because the aptitude of macrophages, fibroblasts, and endothelial cells to move and attach themselves is influenced by integrin interaction with collagen, type 1 collagen is required to recruit macrophages and monocytes. Remarkably, the strength of the chemotaxis stimulation is proportional to the amount of collagen present.
Metalloproteases like collagenase, as well as other types of trauma or enzymatic erosion, cause collagen degradation naturally. When this happens, however, the collagen fragments induce macrophage and fibroblast infiltration in the wound bed. Furthermore, the body recycles any exposed amino acids leftover from the fragmentation process and utilizes them to create new proteins for accelerated wound healing.
When collagen molecules fragment (hydrolyzed), their triple helix form is lost, the function shifts to a more rejuvenated condition by activating monocytes, resulting in the creation of more macrophages, and so on. Nonhydrolyzed collagen particles or powders may improve scaffolding and cell migration in forming granulation tissue. In the wound care market, there are many hydrolyzed collagen formats that do not compare to the high collagen protein structure and healing outcomes as do Medifil® II Collagen Particles.
Properties of Medifil® II Collagen Particles
Clinical Indications of Medifil® II Collagen Particles
Human BioSciences, Inc. blog offers education and tips; however,the information provided by this website or company is not a substitute for medical treatment or advice.
Mrs. Vann is responsible for branding, design, and public outreach efforts for the company. Mrs. Vann has over five years of experience in the creative design arena. She has spearheaded multiple marketing campaigns, both domestic and international. She also has experience producing several television and live-stage programs. She has a Bachelor’s Degree in Film and Video Studies from George Mason University.
Mr. Patel is the Vice President of Operations for Human BioSciences. As such, he is responsible for strategy development for optimal growth, organizing multiple teams and implementing optimal product delivery for the growth of HBS. He has served multiple positions within HBS since 2001, including Operations Manager. With an MBA in Pharmaceutical Healthcare and a Bachelor’s in Pharmaceuticals, Mr. Patel brings deep technical knowledge in collagen product production with a rich history in managing teams.
As the President of Human BioSciences, Dr. Rohan K Jain is responsible for the company’s overall operations, with a focus on research and development. Dr. Jain has supervised and conducted extensive research in the collagen, biomaterials, and protein space, resulting in the release of numerous new products to the market. Prior to his role at HBS, Dr. Jain was a capital markets attorney at Shearman & Sterling LLP. He received his Doctorate in Law and his MBA from New York University; his Bachelor’s degrees in Biomedical Engineering and Materials Science and his Master’s in Engineering Management from Johns Hopkins University. He is a member of the New York and Maryland bars.
Cheryl Carver, LPN, WCC, CWCA, CWCP, DAPWCA, FACCWS is responsible for clinical education and training initiatives for customer accounts. Ms. Carver has amassed a wealth of clinical knowledge and industry experience in her more than 20 years as a board-certified wound care nurse. She has authored over 200 published white papers, ebooks, blogs, and articles for WoundSource and freelance.
Dr. Goebel is responsible for the company’s physical infrastructure and global expansion efforts through partnerships. Prior to joining HBS, Dr. Goebel was Managing Director at the Graf Matuschka Group in Munich, Germany, where he was actively involved in restructuring and privatization in East Germany and Eastern Europe. He was also a member of the American group of the EBRD European Bank for Reconstruction and Development in the privatization of the Russian economy and military complex. He has over forty years’ experience in many different industries including medical devices, pharmacy, and others. Dr. Goebel earned his Doctorate and Postdoctoral degrees in Economics in East Berlin.
Mr. Kumar is responsible for the company’s overall accounting and finance activities with a focus on internal control and taxation.
Mr. Kumar has over 25 years of public and corporate accounting experience. He is a Certified Public Accountant, licensed in the State of Virginia, Maryland, and Washington D.C., and an Enrolled Agent authorized to practice before the Internal Revenue Service. Mr. Kumar is also a Chartered Accountant and fellow member of the Institute of Chartered Accountants of India. Mr. Kumar received his Master’s degree in Commerce from Himalayan University in India.
Mr. Slovick is responsible for all regulatory and quality affairs in the company. Mr. Slovick has worked in regulatory, quality, and clinical services within the medical device and diagnostics industry for nearly 40 years. He founded Methodize Inc., to offer strategic support for approval of medical devices and in vitro diagnostics products. Mr. Slovick has a Bachelor’s degree in Management Information Systems.
Mr. Agarwal is responsible for Corporate Business Development, Sales, and Product Development, both locally and internationally for the company. Mr. Agarwal has over six years of corporate sales and business development experience. He completed his Master of Science in Engineering Management degree from Johns Hopkins University with a technical concentration in Mechanical Engineering. In the past, he has also worked as a fundraising volunteer for three years and thus gained insights in community fundraising and business development. Additionally, he has interned at a manufacturing firm and understood various intricacies involved in manufacturing ranging from the floor level to the supply chain. He has published a paper on Omni Channel Supply Chain and is a certified Lean Six Sigma associate. He has also interned as a business development consultant to a startup for market research and pricing strategies in Israel. Equipped with a combination of management and technical background acquired from his diverse experiences and education, he is perfectly suited to lead the business development efforts for Human BioSciences.
